98%
921
2 minutes
20
Bone grafting procedures are commonly used to manage bone defects in the craniofacial region. Monetite is an excellent biomaterial option for bone grafting, however, it is limited by lack of osteoinduction. Several molecules can be incorporated within the monetite matrix to promote bone regeneration. The aim was to investigate whether incorporating bone forming drug conjugates (C3 and C6) within monetite can improve their ability to regenerate bone in bone defects. Bilateral bone defects were created in the mandible of 24 Sprague-Dawley rats and were then packed with monetite control, monetite+C3 or monetite+C6. After 2 and 4 weeks, post-mortem samples were analyzed using microcomputed tomography, histology and back-scattered electron microscopy to calculate the percentages of bone formation and remaining graft material. At 2 and 4 weeks, monetite with C3 and C6 demonstrated higher bone formation than monetite control, while monetite+C6 had the highest bone formation percentage at 4 weeks. There were no significant differences in the remaining graft material between the groups at 2 or 4 weeks. Incorporating these anabolic drug conjugates within the degradable matrix of monetite present a promising bone graft alternative for bone regeneration and repair in orthopedic as well as oral and maxillofacial applications.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/jbm.b.34598 | DOI Listing |
J Am Acad Orthop Surg
September 2025
From the Department of Orthopedic Surgery, Hospital for Special Surgery, New York, NY (Neitzke, O'Donnell, Buchalter, Chandi, Westrich, and Gausden), the Department of Orthopedic Surgery, University of Wisconsin-Madison, Madison, WI (O'Donnell), and Somers Orthopaedic Surgery & Sports Medicine Group
Introduction: Developmental dysplasia of the hip (DDH) poses challenges for component positioning during total hip arthroplasty (THA) secondary to abnormal bone morphology, soft-tissue contractures, and hip center migration. The objective of this study was to evaluate the radiographic and clinical outcomes of THA for DDH performed with robotic assistance versus manual (M) technique.
Methods: A retrospective review identified 115 patients with Crowe II to IV dysplasia undergoing primary THA at a single institution from 2016 to 2022.
J Clin Oncol
September 2025
Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Networ
J Clin Oncol
September 2025
Xingpeng Luo, MD, Bin Li, MD, and Yinglong Xi, MD, Orthopedic Treatment Center, Southern Central Hospital of Yunnan Province (The First People's Hospital of Honghe State), Mengzi City, China; and Zhixiang Chen, MD, Department of Nephrology, Southern Central Hospital of Yunnan Province (The First Peo
Blood
September 2025
University of Illinois at Chicago, Chicago, Illinois, United States.
Hematopoietic stem cells (HSCs) responsible for blood cell production and their bone marrow regulatory niches undergo age-related changes, impacting immune responses and predisposing individuals to hematologic malignancies. Here, we show that the age-related alterations of the megakaryocytic niche and associated downregulation of Platelet Factor 4 (PF4) are pivotal mechanisms driving HSC aging. PF4-deficient mice display several phenotypes reminiscent of accelerated HSC aging, including lymphopenia, increased myeloid output, and DNA damage, mimicking physiologically aged HSCs.
View Article and Find Full Text PDFPLoS One
September 2025
Orthopaedics, Hebei Medical University Third Hospital, Shijiazhuang, China.
Enoxaparin sodium (ES), a low molecular weight heparin derivative, has recently been recognized for its diverse biological activities. In particular, the ability of heparin to modulate inflammation has been utilized to enhance the biocompatibility of bone implant materials. In this study, we utilized poly (methyl methacrylate) (PMMA), a drug loading bone implant material, as a matrix and combined this with enoxaparin sodium (ES) to create enoxaparin sodium PMMA cement (ES-PMMA) to investigate the regulatory effects of ES on inflammatory responses in bone tissue from an animal model.
View Article and Find Full Text PDF